Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease

Current Pharmaceutical Design

Volumn 10, Issue 25, 2004, Pages 3141-3156

  Du, Da Ming ^a   Carlier, Paul R ^b  

^a PEKING UNIVERSITY   (China)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Bivalent; Butyrylcholinesterase; Dimer; Inhibitor

Indexed keywords

1,5 BIS(4 ALLYLDIMETHYLAMMONIUMPHENYL)PENTAN 3 ONE DIBROMIDE; 6,8 DICHLOROTACRINE; AMBEMONIUM; AZIDE; CAPROCTAMINE; CHOLINESTERASE INHIBITOR; DECAMETHONIUM; DECIDIUM; DIMER; DIPYRIDINIUM; DONEPEZIL; ESTERASE INHIBITOR; GALANTAMINE; GALLAMINE; HUPERZINE A; HUPYRIDONE; MUSCARINIC RECEPTOR BLOCKING AGENT; PA 2 6; POLYAMINE; PROPIDIUM IODIDE; PYRIDINIUM DERIVATIVE; PYRIDONE DERIVATIVE; PZ 6 8; RIVASTIGMINE; TA 1 3; TACRINE; TACRINE DERIVATIVE; TUBOCURARINE CHLORIDE; TZ 2 6; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; DRUG APPROVAL; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME ACTIVE SITE; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ALZHEIMER DISEASE; ANIMALS; BINDING SITES; CHOLINESTERASE INHIBITORS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4544297127     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383412     Document Type: Review

References (92)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science (Washington, D. C.) 2002; 297: 353-356.
2. Moghul S, Wilkinson D. Use of acetylcholinesterase inhibitors in Alzheimer's disease. Expert Rev Neurotherapeutics 2001; 1: 61-69.
3. Relman AS. Tacrine as a treatment for Alzheimer's dementia. N Eng J Med 1990; 324: 349-352.
4. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. J Am Med Assoc 1994; 271: 992-998.
5. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]-piperidine hydrochloride and related compounds. J Med Chem 1995; 38: 4821-4829.
6. Thomsen T, Bickel U, Fischer JP, Kewitz H. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol 1990; 39: 603.
7. Polinsky RJ. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Therap 1998; 20: 634-647.
8. Han Y, Tang X. Preclinical and clinical progress with huperzine A: A novel acetylcholinesterase inhibitor. In: Becker R, Giacobini E, editors. Alzheimer disease: From molecular biology to therapy. Boston: Birkhäuser; 1996; p. 245-250.
9. Kozikowski AP, Tückmantel W. Chemistry, pharmacology, and clinical efficacy of the chinese nootropic agent huperzine A. Acc Chem Res 1999; 32: 641-650.
10. Tang XC, He XC, Bai DL. Huperzine A: A novel acetylcholinesterase inhibitor. Drugs Future 1999; 24: 647-663.
11. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-896.
12. Castro A, Martinez A. Peripheral and dual binding site acetylcholinesterase inhibitors: Implications in treatment of Alzheimer's disease. Mini Rev Med Chem 2001; 1: 267-272.
13. Dorronsoro I, Castro A, Martinez A. Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease-modifying agents. Exp Opin Ther Patents 2003; 13: 1725-1732.
14. Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept®): Implications for the design of new anti-Alzheimer drugs. Structure 1999; 7: 297-307.
15. Paton WDM, Zaimis EJ. Curare-like action of polymethylene bisquaternary ammonium salts. Nature 1948; 161: 718-719.
16. Paton WDM, Zaimis EJ. The pharmacological actions of polymethylene bistrimethylammonium salts. Br J Pharmacol 1949; 4: 381-400.
17. Bergmann F, Wilson IB, Nachmansohn D. The inhibitory effect of stilbamidine, curare, and related compounds and its relationship to the active groups of acetylcholine esterase. Action of stilbamidine on nerve impulse conduction. Biochim Biophys Acta 1950; 6: 217-224.
18. Bergmann F, Segal R. The relationship of quaternary ammonium salts to the anionic sites of true and pseudo cholinesterase. Biochem J 1954; 58: 692-698.
19. Austin L, Berry WK. Two selective inhibitors of cholinesterase. Biochem J 1953; 54: 695-700.
20. Lands AM, Hoppe JO, Arnold A, Kirchner FK. An investigation of the structure-activity correlations within a series of ambenonium analogs. J Pharmacol Exp Ther 1958; 123: 121-127.
21. Webb GD. Affinity of benzoquinonium and ambenonium derivatives for the acetylcholine receptor, tested on the electroplax, and for acetylcholinesterase in solution. Biochim Biophys Acta 1965; 102: 172-184.
22. Hodge AS, Humphrey DR, Rosenberry TL. Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol Pharmacol 1992; 41: 937-942.
23. Mooser G, Schulman H, Sigman DS. Fluorescent probes of acetylcholinesterase. Biochem 1972; 11: 1595-1602.
24. Mooser G, Sigman DS. Ligand binding properties of acetylcholinesterase determined with fluorescent probes. Biochem 1974; 13: 2299-2307.
25. Changeux J-P. Responses of acetylcholinesterase from Torpedo marmorata to salts and curarizing drugs. Mol Pharmacol 1966; 2: 369-392.
26. Taylor P, Lappi S. Interaction of fluorescence probes with acetylcholinesterase. The site and specificity of propidium binding. Biochem 1975; 14: 1989-1997.
27. Berman HA, Decker MM, Nowak MW, Leonard KJ, McCauley M, Baker WM, et al. Site selectivity of fluorescent bisquaternary phenanthridinium ligands for acetylcholinesterase. Mol Pharmacol 1987; 31: 610-616.
28. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, et al. Atomic structure of acetylcholinesterase from Torpedo californica: A prototype acetylcholine-binding protein. Science (Washington, D.C.) 1991; 253: 872-879.
29. Hard M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, et al. Quaternary ligand binding to aromatic residues in the activesite gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993; 90: 9031-9035.
30. Dougherty DA. Cation-π interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp. Science (Washington, D C) 1996; 271: 163-168.
31. Raves ML, Harel M, Pang Y-P, Silman I, Kozikowski AP, Sussman JL. Structure of acetylcholinesterase complexed with the nootropic alkaloid (-)-huperzine A. Nature Struct Biol 1997; 4: 57-63.
32. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 Å resolution. FEBS Lett 1999; 463: 321-326.
33. Felder CE, Harel M, Silman I, Sussman JL. Structure of a complex of the potent and specific inhibitor BW 284c51 with Torpedo californica acetylcholinesterase. Acta Crystallogr, Sect D 2002; 58: 1765-1771.
34. Bourne Y, Taylor P, Radic Z, Marchot P. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site. EMBO J 2003; 22: 1-12.
35. Portoghese PS, Larson DL, Yim CB, Sayre LM, Ronsisvalle G, Tam SW, et al. The relationship of spacer length and selectivity at multiple opioid receptors. J Med Chem 1986; 29: 1855-1861.
36. Portoghese PS. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharm Sci 1989; 10: 230-235.
37. Portoghese PS. The role of concepts in structure-activity relationship studies of opioid ligands. J Med Chem 1992; 35: 1927-1937.
38. Jencks WP. On the attibution and additivity of binding energies. Proc Natl Acad Sci USA 1981; 78: 4046-4050.
39. Pang Y-P, Kozikowski AP. Prediction of the binding sites of huperzine A in acetylcholinesterase by docking studies. J Comput-Aided Mol Design 1994; 8: 669-681.
40. Pang Y-P, Quiram P, Jelacic T, Hong F, Brimijoin S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. J Biol Chem 1996; 271: 23646-23649.
41. Pang Y-P, Hong F, Quiram P, Jelacic T, Brimijoin S. Synthesis of alkylene linked bis-THA and alkylene linked benzyl-THA as highly potent and selective inhibitors and molecular probes of acetylcholinesterase. J Chem Soc Perkin Trans I 1997; 171-176.
42. Carlier PR, Han YF, Chow ES-H, Li CP-L, Wang H, Lieu TX, et al. Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Bioorg Med Chem 1999; 7: 351-357.
43. Wang H, Carlier PR, Ho WL, Wu DC, Lee NTK, Li CPL, et al. Effects of bis(7)-tacrine, a novel anti-Alzheimer's agent, on rat brain AChE. NeuroReport 1999; 10: 789-793.
44. Wang H, Carlier PR, Ho WL, Lee NT-K, Pang Y-P, Han Y-F. Attenuation of scopolamine-induced deficits in navigational performance in rats by bis(7)-tacrine, a novel dimeric AChE inhibitor. Acta Pharm Sin 1999; 20: 211-217.
45. Liu J, Ho W-L, Lee NTK, Carlier PR, Pang Y-P, Ian Y. Bis(7)-tacrine, a novel AChE-inhibitor, reverses AF64A-induced deficits in navigational memory in rats. Neurosci Lett 1999; 282: 165-168.
46. Carlier PR, Chow ES-H, Han Y, Liu J, Yazal JE, Pang Y-P. Heterodimeric tacrine-based acetylcholinesterase inhibitors: Investigating ligand-peripheral site interactions. J Med Chem 1999; 42: 4225-4231.
47. + channel blockers. Investigations on the role of the charged heterocycle. J Med Chem 1995; 38: 595-606.
48. 2+ in blockade of the N-methyl-D-aspartate receptor channel. Mol Pharmacol 1994; 46: 151-160.
49. Bergeron RJ, Weimar WR, Wu Q, Feng Y, McManis JS. Polyamine analogue regulation of NMDA MK-801 binding: A structure-activity study. J Med Chem 1996; 39: 5257-5266.
50. Han YF, Li CP-L, Chow ES-H, Wang H, Pang Y-P, Carlier PR. Dual-site binding of bivalent 4-aminopyridine and 4-aminoquinoline-based AChE inhibitors: Contribution of the hydrophobic alkylene tether to monomer and dimer affinities. Bioorg Med Chem 1999; 7: 2569-2575.
51. + channel blockers related to dequalinium. J Med Chem 1996; 39: 359-370.
52. Paolini JP, Lendvay LJ, Palopoli FP. N4,N4′-decamethylenebis-4-aminopyridine and N9,N9′-decamethyl-9-aminoacridine. J Med Chem 1969; 12: 701-702.
53. Carlier PR, Du D-M, Han Y-F, Liu J, Perola E, Williams ID, et al. Dimerization of an inactive fragment of huperzine A produces a drug with twice the potency of the natural product. Angew Chem Int Ed 2000; 39: 1775-1777.
54. Pomponi M, Marta M, Colella A, Sacchi S, Patamia M, Gatta F, et al. Studies on a new series of THA analogues: Effects of the aromatic residues that line the gorge of AChE. FEBS Lett 1997; 409: 155-160.
55. Savini L, Campiani G, Gaeta A, Pellerano C, Fattoruso C, Chiasserini L, et al. Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem Lett 2001; 11: 1779-1782.
56. Savini L, Gaeta A, Fattorusso C, Catalanotti B, Campiani G, Chiasserini L, et al. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors. J Med Chem 2003; 46: 1-4.
57. Hu M-K, Wu L-J, Hsiao G, Yen M-H. Homodimeric tacrine congeners as acetylcholinesterase inhibitors. J Med Chem 2002; 45: 2277-2282.
58. Gregor VE, Emmerling MR, Lee C, Moore CJ. The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex®) derivatives. Bioorg Med Chem Lett 1992; 2: 861-864.
59. Recanatini M, Cavalli A, Belluti F, Piazzi L, Rampa A, Bisi A, et al. SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: Synthesis, enzyme inhibitory activity, QSAR, and structure-based COMFA of tacrine analogues. J Med Chem 2000; 43: 2007-2018.
60. Xia Y, Kozikowski AP. A practical synthesis of the chinese "nootropic" agent huperzine A: A possible lead in the treatment of Alzheimer's disease. J Am Chem Soc 1989; 111: 4116-4117.
61. Qian L, Ji R. A total synthesis of (±)-huperzine A. Tetrahedron Lett 1989; 30: 2089-2090.
62. Kaneko S, Yoshino T, Katoh T, Terashima S. An enantioselective synthesis of natural (-)-huperzine A via cinchona alkaloidspromoted asymmetric Michael reaction. Heterocycles 1997; 46: 27-30.
63. Kozikowski AP, Xia Y, Reddy ER, Tückmantel W, Hanin I, Tang XC. Synthesis of huperzine A and its analogues and their anticholinesterase activity. J Org Chem 1991; 56: 4636-4645.
64. He XC, Wang ZY, Li YL, Xu ZR, Bai DL. Synthesis of analogues of huperzine A. Chin Chem Lett 1993; 4: 597-600.
65. Fink DM, Bores GM, Effland RC, Huger FP, Kurys BE, Rush DK, et al. Synthesis and evaluation of 5-amino-5,6,7,8-tetrahydroquino-lines as potential agents for the treatment of Alzheimer's disease. J Med Chem 1995; 38: 3645-3651.
66. Kozikowski AP, Campiani G, Nacci V, Sega A, Saxena A, Doctor BP. An approach to modified heterocyclic analogues of huperzine A and isohuperzine A. Synthesis of the pyrimidone and pyrazole analogues, and their anticholinesterase activity. J Chem Soc Perkin Trans I 1996; 1287-1297.
67. Kozikowski AP, Campiani G, Sun L-Q, Wang S, Saxena A, Doctor BP. Identification of a more potent analogue of the naturally occurring alkaloid huperzine A. Predictive molecular modelling of its interaction with AChE. J Am Chem Soc 1996; 118: 11357-11362.
68. Campiani G, Kozikowski AP, Wang S, Ming L, Nacci V, Saxena A, et al. Synthesis and anticholinesterase activity of huperzine A analogues containing phenol and catechol replacements for the pyridone ring. Bioorg Med Chem Lett 1998; 8: 1413-1418.
69. Carlier PR, Du D-M, Han Y-F, Liu J, Pang Y-P. Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors. Bioorg Med Chem Lett 1999; 9: 2335-2338.
70. Dubas-Sluyter MAT, Speckamp WN, Huisman HO. Heterocyclic synthesis via 1-amino-3-oxo-1-cyclohexene. Recueil 1972; 91: 157-160.
71. Camps P, Achab RE, Görbig DM, Morral J, Muñoz-Torrero D, Badia A, et al. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. J Med Chem 1999; 42: 3227-3242.
72. Camps P, Cusack B, Mallender WD, Achab RE, Morral J, Muñoz-Torrero D, et al. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol Pharmacol 2000; 57: 409-417.
73. Wong DM, Greenblatt LIM, Dvir H, Carlier PR, Han Y-F, Pang Y-P, et al. Acetylcholinesterase complexed with bivalent ligands related to huperzine A: Experimental evidence for species-dependent protein-ligand complementarity. J Am Chem Soc 2003; 125: 363-373.
74. Jin GY, He XC, Zhang HY, Bai DL. Synthesis of alkylene-linked dimers of (-)-huperzine A. Chin Chem Lett 2002; 13: 23-26.
75. Mary A, Renko Z, Guillou C, Thal C. Potent acetylcholinesterase inhibitors: Design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. Bioorg Med Chem 1998; 6: 1835-1850.
76. Raskind MA. Update on Alzheimer drugs (galantamine). Neurologist 2003; 9: 235-240.
77. Prendergast MA, Jackson WJ, Terry Jr AV, Decker MW, Arneric SP, Buccafusco JJ. Central nicotinic agonists ABT-418, ABT-089, and (-)-nicotine reduce distractability in adult monkeys. Psychopharm 1998; 136: 50-58.
78. Guillou C, Mary A, Renko DZ, Gras E, Thal C. Potent acetylcholinesterase inhibitors: Design, synthesis and structure-activity relationships of alkylene linked bis-galanthamine and galanthamine-galanthaminium salts. Bioorg Med Chem Lett 2000; 10: 637-639.
79. Melchiorre C, Andrisano V, Bolognesi ML, Budriesi R, Cavalli A, Cavrini V, et al. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. J Med Chem 1998; 41: 4186-4189.
80. Turniatti V, Rosini M, Bartolini M, Cavalli A, Marucci G, Andrisano V, et al. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine. J Med Chem 2003; 46: 954-966.
81. Bunyapaiboonsri T, Ramström O, Lohmann S, Lehn J-M, Peng L, Goeldner M. Dynamic deconvolution of a pre-equilibrated dynamic combinatorial library of acetylcholinesterase inhibitors. Chembiochem 2001; 2: 438-444.
82. Lewis WG, Green LG, Grynszpan F, Radic Z, Carlier PR, Taylor P, et al. Click chemistry in situ: Acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed 2002; 41: 1053-1057.
83. Kolb HC, Finn MG, Sharpless KB. Click chemistry: Diverse chemical function from a few good reactions. Angew Chem Int Ed 2001; 40: 2004.
84. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. Drug Discov Today 2003; 8: 1128-1137.
85. Wu D-C, Xiao X-Q, Ng AKY, Chen PMY, Chung W, Lee NTK, et al. Protection against ischemic injury in primary cultured mouse astrocytes by bis(7)-tacrine, a novel acetylcholinesterase inhibitor. Neurosci Lett 2000; 288: 95-98.
86. Xiao XQ, Lee NT-K, Carlier PR, Pang Y-P, Han YF. Bis(7)-tacrine, a promising anti-Alzheimer's agent, reduces hydrogen-peroxide-induced injury in rat pheochromocytoma cells: Comparison with tacrine. Neurosci Lett 2000; 290: 197-200.
87. Rees TM, Brimijoin S. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs of Today 2003; 39: 75-83.
88. Bartolini M, Bertucci C, Cavrini V, Andrisano V. β-amyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem Pharm 2003; 65: 407-416.
89. Piazzi L, Rampa A, Bisi A, Gobbi S, Belluti F, Cavalli A, et al. 3-(4-{[benzyl(methylamino]methyl}-phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation: A dual function lead for Alzheimer's disease therapy. J Med Chem 2003; 46: 2279-2282.
90. Gualtieri F, Manetti D, Romanelli MN, Ghelardini C. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Dgsign 2002; 8(2): 125-38.
91. Schechter LE, Dawson LA, Harder JA. The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease. Curr Pharm Design 2002; 8(2): 139-45.
92. Schimmoller F, Higaki JN, Cordell B. Amyloid forming proteases: therapeutic targets for Alzheimer's disease. Curr Pharm Design 2002; 8(28): 2521-31.